估值有支撑，关注"更高阶"低估 证券研究报告 固收定期报告 / 2025.11.26 核心观点 相关报告 1. 《城投 2026，风偏分化？》 2025- 11-25 2. 《2026 年度策略：经济 K 型复苏，股债 K 型交易》 2025-11-24 3. 《信用 | 年末或有一定波动 》 2025- 11-23 请阅读最后一页的重要声明！ 分析师 孙彬彬 SAC 证书编号：S0160525020001 sunbb@ctsec.com 分析师 隋修平 SAC 证书编号：S0160525020003 suixp@ctsec.com 分析师 李浩时 SAC 证书编号：S0160525080002 lihs@ctsec.com 联系人 郑惠文 zhenghw01@ctsec.com 联系人 柳婧舒 liujs@ctsec.com ❖ 2026 推动转债走强的"固收资产荒"以及"权益高景气"或延续。一 方面，转债整体股性处于历史高点。基于我们 2026 年年度策略的观点，我们 认为 2026 年股债双牛依然可以期待，权益有较大的想象空间，强权益或成为 2026 年转债表现最重要的支撑。另一方面，结合长端利率保持低 ...

商业航天司设立，助力产业资源战略统筹 国防军工 证券研究报告 行业投资策略周报 / 2025.11.25 投资评级:看好(维持) 最近 12 月市场表现 -11% -3% 5% 13% 21% 29% 国防军工 沪深300 分析师 佘炜超 SAC 证书编号：S0160522080002 shewc@ctsec.com 分析师 杨博星 SAC 证书编号：S0160525060005 yangbx@ctsec.com 联系人 任子悦 renzy01@ctsec.com 相关报告 1. 《福建舰正式入列，太空算力开启航天新 叙事》 2025-11-12 2. 《国防军工 2025 年三季报总结》 2025-11-05 3. 《载人任务发射成功，低空基建迎政策红 利期》 2025-11-04 核心观点 请阅读最后一页的重要声明！ ❖ 国防军工行业行情回顾：近一周(2025/11/15-2025/11/22)国防军工行业 指数涨跌幅(-1.72%)在申万一级行业中排名第 4/31；近一月(2025/10/22- 2025/11/22)国防军工行业指数涨跌幅(-3.82%)在申万一级行业中排名第 21/31；近一年(20 ...

Investment Rating - The report indicates a positive outlook for the humanoid robot industry, suggesting it is a promising investment opportunity with significant growth potential in the coming years [1]. Core Insights - The humanoid robot sector is expected to see mass production starting in 2026, with projected output levels of 50,000 to 100,000 units [2][9]. - The report highlights that the first wave of market momentum was driven by Elon Musk's announcement regarding production targets, while the second wave was influenced by a performance at the Spring Festival Gala [2][10]. - The overall market size for humanoid robots could reach 140 billion yuan if large-scale production of 1 million units is achieved, with an estimated cost of 140,000 yuan per unit [3][19]. - The industrialization of humanoid robots is accelerating, with major companies like Unitree Technology and UBTECH Robotics securing significant orders and preparing for IPOs [4][34]. Summary by Sections Humanoid Robot Market Review and Outlook - The report reviews the 2025 market performance, noting two key phases of growth driven by high-profile announcements and events [2][9]. - Future catalysts include the release of Tesla's Optimus Generation 3 and the anticipated IPOs of domestic companies [10][22]. Humanoid Robot Price and Volume Analysis - The report estimates that the cost structure of humanoid robots will see a breakdown with significant portions attributed to linear and rotational actuators [19][20]. - The market is expected to grow substantially with mass production, indicating a clear path for industrialization [22]. Acceleration of Humanoid Robot Industrialization - Major players in the industry are ramping up production capabilities and securing large orders, indicating a robust growth trajectory [4][29][31]. - The report identifies three categories of domestic players: established robot manufacturers, automotive companies, and internet giants, each leveraging their strengths in the humanoid robot space [23]. Investment Recommendations - The report suggests focusing on companies with strong order visibility and significant value in the supply chain, such as Top Group and Sanhua Intelligent Control [5][38]. - It also highlights the importance of monitoring core component suppliers that have secured orders or are undervalued [5][38].

灯塔引领品质房企，精益求精笃行向上 建发国际集团(01908) 证券研究报告 房地产开发 / 公司深度研究报告 / 2025.11.24 投资评级:买入(首次) | 基本数据 | 2025-11-24 | | --- | --- | | 收盘价(元) | 16.95 | | 流通股本(亿股) | 22.40 | | 每股净资产(元) | 13.14 | | 总股本(亿股) | 22.40 | 最近 12 月市场表现 -19% -4% 12% 28% 44% 60% 建发国际集团 恒生指数 房地产开发 分析师 房诚琦 SAC 证书编号：S0160525090002 fangcq@ctsec.com 分析师 何裕佳 SAC 证书编号：S0160525090001 heyj@ctsec.com 分析师 陈思宇 SAC 证书编号：S0160525090008 chensy04@ctsec.com 相关报告 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | -- ...

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

Report Industry Investment Rating - No relevant content provided Core Viewpoints - The weekly technical analysis of treasury bond futures shows that the neckline of the head-and-shoulders bottom of the 30-year treasury bond futures was broken, weakening the pattern, and attention should be paid to the subsequent repair strength. TL2603 fell back after a rebound and is in a short-term adjustment. If it further declines after the repair, subsequent market conditions need to be dealt with cautiously [1]. - The data tracking of treasury bond futures indicates that the main contract is about to change, and the cash-and-carry strategy of the 2603 contract still has some participation value. This week, the performance of treasury bond futures was differentiated, and the trading activity increased overall. The CTD net basis of the 2603 contract decreased overall, and the IRR increased except for TL. Currently, the IRR of T2603 and TL2603 is still significantly higher than the capital interest rate [2]. Summary by Directory 1. Weekly Technical Analysis 1.1 Pre - trend Review - This week, the trends of T and TL were differentiated. T rose slightly, while TL declined continuously since Wednesday. TL2603 first rose and then fell, and TL2512 broke below the upper edge of the bottom area (around 115.57) on Friday, breaking the neckline of the head-and-shoulders bottom pattern and closing near the 60 - day line [6]. 1.2 Subsequent Market Outlook - TL2603 showed signs of weakening after breaking below the neckline of the head-and-shoulders bottom on Friday. From the perspective of the wave theory, the adjustment since November 5th may form a platform type, and it may be at the end of the short - term adjustment. Attention should be paid to the repair strength. If the market declines again after the repair, the risk of further continuation of the adjustment needs to be concerned. TL2603 was weaker than T2603 this week. T2603 also broke below 115.57 on Friday, weakening the pattern. If the end of the platform type forms a phased low, the subsequent market can still be optimistic [9]. 2. Weekly Tracking of Treasury Bond Futures - This week, the performance of treasury bond futures was differentiated. As of November 21st, the closing prices of the 2512 contracts of 2 - year, 5 - year, 10 - year, and 30 - year treasury bond futures were 102.460, 105.855, 108.430, and 115.57 yuan respectively, with changes of +0.006, -0.020, +0.015, and -0.59 yuan compared with the previous week [15]. - The trading activity of treasury bond futures increased overall this week. The average daily trading volume of the 2512 contracts of each maturity increased compared with last week, and the trading volume/holding volume increased for each maturity [15]. - As of November 21st, the holding volume of the 2512 contracts of treasury bond futures decreased across the board, while that of the 2603 contracts increased across the board, indicating that participants continued to shift positions [15]. - As of November 21st, the CTD net basis of the 2603 contracts of each maturity decreased overall, with little change in TL. The CTD net basis of the 2512 contracts of 2 - year, 5 - year, 10 - year, and 30 - year were -0.07, -0.05, -0.11, and -0.13 yuan respectively. In terms of IRR, the IRR of the CTD of the 2603 contracts of 2 - year, 5 - year, 10 - year, and 30 - year were 1.66%, 1.60%, 1.77%, and 1.75% respectively, increasing except for TL. The cash - and - carry strategies of T2603 and TL2603 still have some participation value. The spread between the 2512 - 2603 contracts decreased overall this week [18].

3Q2025 符合预期，业绩超预期 万物新生(REREN) 证券研究报告 商贸零售 / 公司点评 / 2025.11.23 1. 《掘金循环经济，增长飞轮已启动》 2025-07-15 2. 《掘金循环经济，增长飞轮已启动》 2025-07-10 核心观点 投资评级:买入(维持) | 基本数据 | 2025-11-20 | | --- | --- | | 收盘价 (美元) | 4.07 | | 流通股本(亿股) | 0.88 | | 每股净资产(美元) | 2.605 | | 总股本(亿股) | 2.2 | 最近 12 月市场表现 -30% -10% 10% 30% 50% 70% 万物新生 标普500 分析师 孙谦 SAC 证书编号：S0160525060001 sunqian@ctsec.com 分析师 邢瀚文 SAC 证书编号：S0160525050001 xinghw@ctsec.com 分析师 张尤 SAC 证书编号：S0160525070001 zhangyou@ctsec.com 相关报告 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A ...

生猪产能去化或加速，宠物内销增长亮眼 农林牧渔 证券研究报告 行业投资策略周报 / 2025.11.23 投资评级:看好(维持) 最近 12 月市场表现 -8% -2% 5% 11% 17% 23% 农林牧渔 沪深300 分析师 王聪 SAC 证书编号：S0160525110001 wangcong@ctsec.com 分析师 肖珮菁 SAC 证书编号：S0160524070005 xiaopj@ctsec.com 相关报告 1. 《宠物双十一国产品牌表现亮眼》 2025-11-16 2. 《生猪供应仍存压力，产能去化或加速》 2025-11-09 3. 《生猪养殖持续亏损，产能去化或加速》 2025-11-02 农业重点数据跟踪周报 核心观点 | 表 1：重点公司投资评级 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 代码 | 公司 | 总市值（亿 | 收盘价 | | EPS（元） | | | PE | | 投资评级 | | | | 元） | （11.21） | 2024 ...

利率 | 股跌了，债为什么不涨？ 证券研究报告 固收定期报告 / 2025.11.23 核心观点 相关报告 1. 《流动性 | 月 末 资 金 的 规 律 ？ 》 2025-11-22 2. 《高频｜杭州新房销售回暖，开工率大多 下行 》 2025-11-22 3. 《固收 + ，加什么？ — — 资产篇》 2025-11-19 请阅读最后一页的重要声明！ 分析师 孙彬彬 SAC 证书编号：S0160525020001 sunbb@ctsec.com 分析师 隋修平 SAC 证书编号：S0160525020003 ❖ 今年三季度股债跷跷板效应十分显著，但近期股市下跌时债市依旧较弱，为 什么？从宏观逻辑上，债市的增量利好有限、货币政策方向不明确是主要原 因；从机构行为角度，一方面是保险赎回固收+产品，另一方面是券商和农商 砸盘。展望未来，货币政策的基调是动态的，我们认为明年初降准降息的可 能性较高，而且从历史出发，无论是 12 月还是中央经济工作会议的日历效应 都很清晰，未来 1-3 周利率行情可能正式开启，建议把握做多机会。 ❖ 股市下跌主因：一是外围因素，隔夜美股大跌，再度引发全球市场对 AI 泡沫 的担忧 ...

Group 1 - The report highlights a strategic shift towards large financial and consumer sectors, indicating a rebound window following the maximum negative impact from equal tariffs [1][9] - The report emphasizes that the market is approaching a phase bottom, with short-term adjustments not altering the long-term upward trend, despite liquidity pressures from the Federal Reserve's hawkish stance [2][9] - Historical analysis of the U.S. stock market shows that significant downturns typically require major negative shocks, with expected maximum adjustments around 10% in the current context [3][10][11] Group 2 - The report notes that market volume has decreased, with transaction amounts falling below 20 trillion yuan, indicating a lack of momentum in market leadership [4][12] - It suggests that the current market adjustment presents a good opportunity for accumulation, focusing on sectors with favorable risk-reward ratios, such as real estate and resource commodities [4][13][14] - The report identifies mid-term investment opportunities in high-growth sectors, waiting for renewed confidence in high-prosperity segments like storage and AI [4][13][14]